Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial - Takeaways - MDSpire

Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial

  • By

  • Joseph Geraci

  • Bessi Qorri

  • Mike Tsay

  • Christian Cumbaa

  • Paul Leonczyk

  • Larry Alphs

  • Elizabeth D. Ballard

  • Carlos A. Zarate

  • Luca Pani

  • December 8, 2025

  • 0 min

Share

  • 1

    NetraAI is an explainable AI platform designed to enhance clinical trial participant selection by identifying high-effect-size patient subpopulations.

  • 2

    In a Phase II study on treatment-resistant depression, NetraAI improved predictive accuracy by 25-30% compared to traditional machine learning models.

  • 3

    The platform identified a 10-clinical variable model that increased predictive AUC by 0.32 over standard models, demonstrating superior performance.

  • 4

    NetraAI's approach allows for the discovery of interpretable patient subgroups, facilitating prospective enrichment in clinical trials.

  • 5

    This innovative AI method has the potential to improve trial success rates and support personalized medicine across various therapeutic areas.

Original Source(s)

Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial

  • by Joseph Geraci, Bessi Qorri, Mike Tsay, Christian Cumbaa, Paul Leonczyk, Larry Alphs, Elizabeth D. Ballard, Carlos A. Zarate, Luca Pani

  • December 8, 2025

Related Content

Research on the Application of Tree Drawing Projection Tests in the Condition Assessment of Depression

Digital mental health interventions in Chinese: a scoping review

The Oversight of Mental Illness in Conversations Surrounding 'Brain Health